ACC/AHA guideline update: Treatment of heart failure with reduced left ventricular ejection fraction

Geriatrics

Volumn 61, Issue 3, 2006, Pages 22-29

  Aronow, Wilbert S ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Guidelines; Heart failure; Systolic

Indexed keywords

ACEBUTOLOL; ALCOHOL; ALDOSTERONE ANTAGONIST; AMILORIDE; AMLODIPINE BESYLATE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ATENOLOL; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BISOPROLOL FUMARATE; BUMETANIDE; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN HEXETIL; CAPTOPRIL; CARVEDILOL; CHLOROTHIAZIDE; CHLORTALIDONE; CLONIDINE; COER; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; ENALAPRIL MALEATE; EPLERENONE; EPROSARTAN; FELODIPINE; FOSINOPRIL; FUROSEMIDE; GUANFACINE; HYDRALAZINE; HYDROCHLOROTHIAZIDE; ILLICIT DRUG; INDAPAMIDE; IRBESARTAN; ISRADIPINE; LABETALOL; LISINOPRIL; LOSARTAN POTASSIUM; METHYLDOPA; METOLAZONE; METOPROLOL; METOPROLOL SUCCINATE; METOPROLOL TARTRATE; MINOXIDIL; MOEXIPRIL; NADOLOL; NICARDIPINE; NIFEDIPINE; NISOLDIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; OLMESARTAN; PENBUTOLOL; PERINDOPRIL; POLYTHIAZIDE; PRAZOSIN; PROPRANOLOL; QUINAPRIL; RAMIPRIL; SPIRONOLACTONE; TELMISARTAN; TERAZOSIN; TIMOLOL MALEATE; TORASEMIDE; TRANDOLAPRIL; TRIAMTERENE; UNINDEXED DRUG; VALSARTAN; VERAPAMIL;

AGING; ALCOHOL ABUSE; ARTERY DISEASE; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOMYOPATHY; CARDIOTOXICITY; CORONARY ARTERY DISEASE; DEFIBRILLATOR; DIABETES MELLITUS; DYSLIPIDEMIA; EXERCISE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MORTALITY; PRACTICE GUIDELINE; RHEUMATIC FEVER; SUDDEN DEATH; UNITED STATES; VALVULAR HEART DISEASE;

AGED; CARDIAC OUTPUT, LOW; CARDIOVASCULAR AGENTS; COMBINED MODALITY THERAPY; DEATH, SUDDEN, CARDIAC; EXERCISE; HEART FAILURE, CONGESTIVE; HUMANS; RECURRENCE; RISK FACTORS; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 33645074917     PISSN: 0016867X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2005; 46(6):1116-43. Available online at: http://www.acc.org/clinical/guidelines/ failure/index.pdf. Accessed Feb. 22, 2006.
2. Aronow WS, Ahn C, Gutstein H. Prevalence and incidence of cardiovascular disease in 1160 men and 2464 older women in a long-term health care facility. J Gerontol A Biol Sci 2002; 57(1):M45-6.
3. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: Executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2001; 38(7):2101-13.
4. Aronow WS, Ahn C, Kronzon I. Prognosis of congestive heart failure in elderly patients with normal versus abnormal left ventricular systolic function associated with coronary artery disease. Am J Cardiol 1990; 66(17):1257-9.
5. Pernenkil R, Vinson JM, Shah AS, et al. Course and prognosis in patients ≥ 70 years of age with congestive heart failure and normal versus abnormal left ventricular ejection fraction. Am J Cardiol 1997; 79(2):216-9.
6. Aronow WS, Ahn C, Kronzon I. Prognosis of congestive heart failure after prior myocardial infarction in older men and women with abnormal versus normal left ventricular ejection fraction. Am J Cardiol 2000; 85(11):1382-4.
7. Vasan RS, Larson MG, Benjamin EJ, et al. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction. J Am Coll Cardiol 1999; 33:1948-55.
8. Gottdiener JS, McClelland RL, Marshall R, et al. Outcome of congestive heart failure in elderly persons: Influence of left ventricular systolic function. The Cardiovascular Health Study. Ann Intern Med 2002; 137(8):631-9.
9. Lee DS, Tu JV, Juurlink DN, et al. Risk-treatment mismatch in the pharmacotherapy of heart failure. JAMA 2005; 294(10):1240-7.
10. Aronow WS. Epidemiology, pathophysiology, prognosis, and treatment of systolic and diastolic heart failure in elderly patients. Heart Dis 2003; 5(4):279-94.
11. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316(23):1429-35.
12. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325(5):303-10.
13. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325(5):293-302.
14. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342(8875):821-8.
15. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995; 273(18):1450-6.
16. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial. Lancet 1999; 353(9146):9-13.
17. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353(9169):2001-7.
18. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in chronic heart failure. N Engl J Med 2001; 344(22):1651-8.
19. Aronow WS, Ahn C, Kronzon I. Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction ≥ 40% treated with diuretics plus angiotensin-converting enzyme inhibitors. Am J Cardiol 1997; 80(2):207-9.
20. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: The CHARM-Alternative trial. Lancet 2003; 362(9386):772-6.
21. Aronow WS. Exercise therapy for older persons with cardiovascular disease. Am J Geriatr Cardiol 2001; 10(5):245-9.
22. Rich MW, Beckham V, Wittenberg C, et al. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med 1995; 333(18):1190-5.
23. Knight BP, Goyal R, Pelosi F, et al. Outcome of patients with nonischemic cardiomyopathy and unexplained syncope treated with an implantable defibrillator. J Am Coll Cardiol 1999; 33(7):1964-70.
24. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352(3):225-37.
25. Aronow WS. CRT plus ICD in congestive heart failure: Use of cardiac resynchronization therapy and an implantable cardioverter-defibrillator in heart failure patients with abnormal left ventricular dysfunction. Geriatrics 2005; 60(2):24-8.
26. Cleland JGF, Daubert J-C, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005; 352(15):1539-49.
27. Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004; 351(20):2049-57.
28. Aronow WS. Race, drugs, and heart failure. Geriatrics 2005; 60(7):8-9.
29. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341(10):709-17.
30. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348(14):1309-21.
31. Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 2002; 347(18):1403-11.
32. Ahmed A, Aronow WS, Fleg JL. Predictors of mortality and hospitalization in women with heart failure in the Digitalis Investigation Group trial. Am J Therap In press